MethA Syngeneic Model Overview
The MethA syngeneic model is a murine fibrosarcoma system derived from BALB/c mice. It is one of the most historically important and widely studied tumor models in immuno-oncology, particularly in the fields of cancer immunotherapy, inflammation, and macrophage activation. MethA tumors are immunogenic, fast-growing, and capable of eliciting strong adaptive immune responses, making this model a cornerstone for studying tumor–immune interactions and immunotherapy mechanisms.
When implanted subcutaneously or intraperitoneally into BALB/c mice, MethA cells form solid, vascularized tumors with consistent growth kinetics. Depending on the route of administration, the model can be adapted to study localized tumor formation, peritoneal carcinomatosis, or immune memory responses. Its reproducibility and immunogenic nature have made MethA a foundational system for evaluating immune checkpoint inhibitors, cytokine therapies, and experimental cancer vaccines.
Request a Custom Quote for MethA Syngeneic ModelBiological and Molecular Characteristics
The MethA fibrosarcoma cell line was originally induced in a BALB/c mouse using the chemical carcinogen methylcholanthrene. The resulting tumor cells display spindle-shaped fibroblast-like morphology and retain stable genetic and phenotypic characteristics across passages. MethA tumors express major histocompatibility complex (MHC) class I molecules and tumor-associated antigens that can activate T-cell–mediated immune responses.
This model is known for its intermediate level of immunogenicity—sufficient to elicit anti-tumor immune responses yet resistant enough to allow progressive tumor formation under normal conditions. The tumor microenvironment includes macrophages, dendritic cells, fibroblasts, and T lymphocytes, along with regulatory immune cells that contribute to immune modulation. MethA is highly responsive to immune stimulation, cytokine therapy, and tumor rejection following adoptive T-cell transfer, making it a benchmark system in experimental immunotherapy.
| Parameter | Description |
|---|---|
| Host strain | BALB/c (female, 6–8 weeks) |
| Tumor origin | Chemically induced fibrosarcoma (mouse) |
| Histological type | Fibrosarcoma |
| Inoculation route | Subcutaneous or intraperitoneal |
| Tumor take rate | >90% |
| Doubling time | Approximately 3–5 days in vivo |
| Metastatic potential | Low; locally invasive |
| Immunophenotype | Highly immunogenic; macrophage and T-cell infiltration |
| Common applications | Immunotherapy, vaccine development, cytokine studies, macrophage activation research |
In Vivo Model Development and Tumorigenicity
MethA tumors can be established by subcutaneous or intraperitoneal implantation of viable tumor cells into BALB/c mice. Subcutaneous inoculation produces solid, measurable tumors that grow consistently and predictably, allowing accurate evaluation of therapeutic efficacy. Intraperitoneal injection, on the other hand, results in diffuse tumor nodules suitable for studying systemic immunotherapy or adoptive T-cell transfer.
Tumors typically develop within 5–7 days following inoculation, with uniform take rates and reproducible progression across experimental cohorts. The MethA model’s high immunogenicity makes it ideal for studies investigating immune checkpoint blockade, vaccine-induced tumor rejection, and tumor-associated macrophage reprogramming. Because immune memory can be established following tumor clearance, the model also supports investigations of long-term immunity and relapse prevention.
Request a Custom Quote for MethA Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological analysis of MethA tumors reveals densely packed spindle-shaped cells arranged in interlacing fascicles, characteristic of fibrosarcoma. The tumors are moderately vascularized, with areas of necrosis and peripheral inflammatory infiltrates. Collagen deposition within the stroma and infiltration by immune cells contribute to the tumor’s fibrotic appearance.
Immunohistochemical staining confirms vimentin expression, verifying mesenchymal origin, and demonstrates strong Ki-67 staining indicative of active proliferation. CD3 and CD8 staining highlight extensive T-cell infiltration, while F4/80 identifies macrophages distributed throughout the tumor microenvironment. PD-L1 expression is detectable and increases following cytokine exposure, reflecting active immune engagement. The presence of both effector and regulatory immune populations makes MethA particularly suitable for mechanistic studies of immune activation, suppression, and tumor clearance.
Preclinical Applications and Drug Response
The MethA syngeneic model has played a pivotal role in the development of modern cancer immunotherapy. It was among the first models used to demonstrate tumor rejection following adoptive T-cell transfer and cytokine therapy. MethA tumors respond to interferon, interleukin-based treatments, and immune checkpoint blockade, especially when combined with radiation or immune adjuvants. The model’s immunogenicity allows direct investigation of tumor-specific T-cell responses and immune memory formation.
MethA is frequently employed in studies of tumor-associated macrophage modulation, dendritic cell activation, and vaccine-induced immunity. It also serves as a robust system for testing novel immunomodulatory agents, oncolytic viruses, and combination therapies that convert immune-cold tumors into immune-active states. Its long history and proven reproducibility have established MethA as a classic model for dissecting immune-mediated mechanisms of tumor control and regression.
Request This Model
To request the MethA syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for MethA Syngeneic Model